Latest Content

Bryan Dennison breaks down the purpose-built technology behind ClaimGuardRx and how its detect-and-respond design keeps manufacturers ahead of evolving diversion tactics.

Matt Turner shares how ClaimGuardRx is redefining patient affordability by turning claims data into a proactive defense against maximizers and accumulators.

Overhaul's Danny Ramon argues that quality and regulatory teams, not just logistics, need faster protocols and more accessible stability data, since stolen or compromised product that re-enters the supply chain through gray markets can ultimately reach patients.

Cencora's Ameer Ali explains why trading partners' systems, not the NDC-12 deadline itself, determine whether product keeps moving through the supply chain during the transition.

Ed Schoonveld examines the uncertainty surrounding President Trump's MFN drug pricing agreements, stalled GENEROUS, GLOBE and GUARD proposals, and their ripple effects on ex-US drug launches.

Cencora's Gregg Gorniak on where DSCSA trading partners find shared value in compliance investment, and where that alignment breaks down.

In this week's Pharma Pulse, nine more drugmakers join the MFN program, GoodRx adds a family plan, IPC formalizes its USave partnership, and CSafe expands its thermal cover offerings.

McKesson's Scott Mooney discusses the technical and operational challenges of DSCSA compliance, from linking ERP systems to EPCIS to recurring friction in 340B transaction data exchange.

HDA's Kala Shankle says a two-year national licensure runway for distributors could work, but only if states, the FDA and industry move in parallel.

The acquisition formalizes a nearly decade-old partnership as independent pharmacies lean on cooperatives to offset PBM reimbursement pressure and closures.

Cardinal Health's Liberty Dewey breaks down the NDC-12 transition timeline and the vendor, association and wholesaler support smaller pharmacies will need to get ready.

As loss-of-exclusivity events accelerate, generics and biosimilars are diverging into distinct business models, demanding different regulatory, IP, and market access strategies from manufacturers.

Cencora's Gregg Gorniak breaks down what separates basic DSCSA compliance from using it to streamline transactions and strengthen trading partnerships.